Loading…
Loading…
NNOX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for NNOX and 80,000+ other tickers.
See exactly how NNOX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NNOX and 80,000+ other tickers.
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based…
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information, are preliminary and unaudited, and are subject to change upon completion of the Company's financial close process, final adjustments, management review and other internal procedures, and review by its independent auditors.
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, established healthcare industry relationships, and expertise in introducing advanced medical technologies.
Nanox.ARC X recognized among the “world's most groundbreaking innovations” and for its approach to making advanced medical imaging more accessible
Shares of Nano-X Imaging Ltd. (NASDAQ: NNOX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and
Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd.